Navigation Links
Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:6/18/2013

@baml.com">dg.prospectus_requests@baml.com; or Citigroup c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at 1-800-831-9146 or email at batprospectusdept@citi.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma.

For more information about Intercept, please contact Mark Pruzanski, MD, or Barbara Duncan, both of Intercept Pharmaceuticals at 1-646-747-1000. 

 


'/>"/>
SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
3. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
4. Intercept Pharmaceuticals Closes $30 Million Series C Financing
5. Valeant Pharmaceuticals Prices Public Offering Of Common Shares
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
8. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
9. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
10. Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
11. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... Nov. 12 A new treatment for autism appears ... S. Starr, MD, FAACAP, BCIA-EEG. , In ... characteristically common "u" EEG pattern reflecting impaired brain function, ... interaction, communication, speech and bonding. , ...
... MINNEAPOLIS/ST. PAUL, Nov. 12 /PRNewswire / -- ... for Integrative Oncology,s (SIO) Sixth International Conference in ... and safety of complementary and alternative medicine (CAM) ... Director, Hematology/Oncology at Children,s Hospitals and Clinics of ...
Cached Medicine Technology:New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
(Date:12/21/2014)... 21, 2014 Serious Buyer, Andrew Hawley ... Jm Morrison and the Doors International Ballroom at the ... also be the only time that Morrison's mother would ... Nov. 25, 1967. According to Hawley, “This would be ... play the Alexandria Roller Rink earlier that year and ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings on ... clots from using testosterone products such as AndroGel and ... the male hormone testosterone may increase the risk of ... the Proceedings of the National Academy of Sciences in ... male rats with naturally occurring colon cancer. Dr. Amos-Landgraf, ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 BambooIndustry.com ... . Recently, the business has announced its bamboo ... buys the best material from certified suppliers, and ... its customers worldwide. In the current promotion, all ... 20% off, when they say they know BambooIndustry.com ...
(Date:12/20/2014)... 2014 DePuy Pinnacle hip lawsuits ... of the artificial hip system was defectively designed ... courts, Bernstein Liebhard LLP reports. According to an ... Court on December 2nd, counsel in 10 DePuy ... plaintiffs on November 19, 2014, with depositions to ...
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... new study it was found that in case of ... above, their mental abilities are on the decline due ... York City at the 21st Annual Scientific Meeting of ... measured blood pressure and cognitive function in 101 Japanese ...
... signaling pathways in the immune cells that seem to point ... system.// This new research could be important in uncovering for ... entry into the cells. ,The cell culture study ... and the University of Pennsylvania appears in the Proceedings of ...
... American Journal of Respiratory and Critical Care Medicine says that ... in lung capacity equivalent to what usually happens after 12 ... ,An average loss of 372 milliliters was noted, which ... loss is at least 10 times more than the annual ...
... Anti-depressant Prozac’s journey in the brain and its ultimate ... Spring Harbor Laboratory on Long Island. //This finding will ... will have relatively lesser side effects. ,The ... the factors that control how, when, and where new ...
... A new study that has thrown light on allergic reactions ... children who get bitten by insects are in need of ... display any adverse allergic symptoms. ,The study, entitled “Allergic reactions ... junior high school children in Israel” can be found in ...
... the University of California, San Francisco (UCSF) it is possible ... supplements in infants and children are a novel method for ... the Department of General Pediatrics at UCSF Children's Hospital and ... is no specific way by which one can prevent asthma. ...
Cached Medicine News:Health News:As You Age Check Your BP for It Can Affect Your Mental Ability 2Health News:Link Between Immune System And Nervous System 2Health News:Ultimate Destination of anti-depressant, Prozac 2Health News:Insect Bites Among Children Do Not Warrant Medical Attention In Most Cases 2Health News:Introduction of Microbial Organisms: A Possible Treatment for Asthma 2
The safePICO is a prebarcoded arterial sampler that helps you ensure patient and caregiver safety. SafePICO is part of 1st automatic, the worlds first automatic blood gas analysis system....
Measure SpO2 and tcpCO2 with a single sensor....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: